Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 318 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Spinal Arthritis Clear all
Completed Early Phase 1 Interventional

A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector

NCT00643526
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis
Interventions
Pre-filled Auto-injector Containing Placebo
Device
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Miami, Florida • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 17, 2026, 5:56 PM EDT
Active, not recruiting Not applicable Interventional

Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity

NCT05715463
View directory record Official record
Conditions
Rheumatoid Arthritis, Palindromic Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Sacroiliitis, Psoriatic Arthritis, Mixed Connective Tissue Disease, Lupus, Enteropathic Arthropathies, Systemic Sclerosis, Sjogren's Syndrome, Sicca Syndrome, Inflammatory Arthritis, Undifferentiated Connective Tissue Diseases
Interventions
Resource sheets, Community Resource Specialist, Nurse Navigator
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

NCT04018599
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 17, 2026, 5:56 PM EDT
Terminated Phase 2 Interventional Results available

PsA Treatment With hOKT3γ1 (Ala-Ala)

NCT00239720
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
hOKT3gamma1(Ala-Ala), Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Aurora, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 17, 2026, 5:56 PM EDT
Recruiting No phase listed Observational

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

NCT07403188
View directory record Official record
Conditions
Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis, Dermatomyositis, Systemic Sclerosis (SSc)
Interventions
KYV-101
Drug
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2041
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

NCT00195689
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Human anti-TNF monoclonal antibody/adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 29, 2007 · Synced Oct 17, 2026, 5:56 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Psoriatic Arthritis Study of Izokibep

NCT05623345
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Izokibep, Placebo to izokibep
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
40
States / cities
Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis

NCT01752634
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab (AIN457), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
21
States / cities
Peoria, Arizona • Aventura, Florida • Palm Harbor, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 17, 2026, 5:56 PM EDT
Active, not recruiting Phase 4 Interventional

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

NCT06864026
View directory record Official record
Conditions
Psoriatic Arthritis, Overweight or Obesity
Interventions
Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
53
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 5:56 PM EDT
Recruiting Phase 1 Interventional

Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain

NCT06361485
View directory record Official record
Conditions
Low Back Pain
Interventions
Lumbar Injections with 10cc's of Wharton's Jelly Allograft
Biological
Lead sponsor
R3 Stem Cell
Industry
Eligibility
20 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Scottsdale, Arizona • Beverly Hills, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 17, 2026, 5:56 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

NCT02438787
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 17, 2026, 5:56 PM EDT
Active, not recruiting No phase listed Observational

Psoriasis Longitudinal Assessment and Registry

NCT00508547
View directory record Official record
Conditions
Psoriasis
Interventions
Not listed
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
20,167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
167
States / cities
Birmingham, Alabama • Florence, Alabama • Huntsville, Alabama + 164 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 5:56 PM EDT
Not yet recruiting Phase 4 Interventional

A Clinical Trial of Antiplatelets in Psoriasis

NCT07744191
View directory record Official record
Conditions
Psoriasis (PsO), Psoriatic Arthritis (PsA)
Interventions
Aspirin, Clopidogrel, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

NCT04436640
View directory record Official record
Conditions
Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Glendale, Arizona • Phoenix, Arizona • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 17, 2026, 5:56 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

NCT07801495
View directory record Official record
Conditions
Moderate to Severe Psoriatic Arthritis
Interventions
DDY391, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Memphis, Tennessee • Colleyville, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

NCT04209205
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
AIN457 6 mg/kg i.v., Placebo, AIN457 3 mg/kg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
31
States / cities
Birmingham, Alabama • Fountain Valley, California • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Activating the Cholinergic Anti-Inflammatory Pathway in Healthy Volunteers and People With Inflammatory Arthritis

NCT06555562
View directory record Official record
Conditions
Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions
Ultrasound Stimulation, Non-active ultrasound stimulation
Device
Lead sponsor
Surf Therapeutics
Industry
Eligibility
22 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Austin, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

NCT01087788
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
27
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 17, 2026, 5:56 PM EDT
Completed No phase listed Observational

Treatment Goals in Psoriatic Arthritis

NCT03620188
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Standard of care
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 95 Years
Enrollment
250 participants
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 17, 2026, 5:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA

NCT03011242
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01212770
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis

NCT05153148
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
NDI-034858, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
23
States / cities
Palm Desert, California • Upland, California • Hollywood, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 17, 2026, 5:56 PM EDT
Recruiting Phase 4 Interventional

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

NCT06454188
View directory record Official record
Conditions
Psoriatic Arthritis, Spondyloarthritis, Axial
Interventions
Upadacitinib 15 MG [Rinvoq], Placebo
Drug
Lead sponsor
CARE ARTHRITIS LTD.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Cleveland, Ohio • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 17, 2026, 5:56 PM EDT
Not listed No phase listed Observational

Burst Biologics Spinal Fusion Registry

NCT03064802
View directory record Official record
Conditions
Degenerative Disc Disease, Spinal Stenosis, Spondylitis, Spondylolisthesis, Herniated Disk
Interventions
BioBurst Fluid, Burst Allograft
Device
Lead sponsor
Burst Biologics
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Carrollton, Georgia • Paducah, Kentucky • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 17, 2026, 5:56 PM EDT